Comparative Pathogenesis of Crimean-Congo Hemorrhagic Fever and Ebola Hemorrhagic Fever

  • Mike Bray

Crimean-Congo hemorrhagic fever (CCHF) virus has been called “the Asian Ebola virus” – an epithet that recognizes the close clinical resemblance of CCHF and Ebola hemorrhagic fever (EHF), and also suggests that the two illnesses share similar underlying mechanisms [38]. CCHF and EHF both present difficult challenges to pathophysiology research, because they occur principally in regions lacking a modern medical infrastructure and because the high virulence of their causative agents requires laboratory studies to be performed under Biosafety Level 4 (BSL-4) containment. Efforts to elucidate the pathogenesis of CCHF have been even further handicapped by the failure of the virus to cause disease in laboratory animals other than suckling mice. By contrast, models of EHF in adult mice, guinea pigs, and nonhuman primates have been employed extensively for pathogenesis studies [7, 13, 24]. Detailed examination of clinical and laboratory parameters, pathologic changes, and innate immune responses in cynomolgus macaques over the entire course of fatal EHF has been especially valuable in elucidating how the pathogen overcomes host defenses to cause rapidly overwhelming infection. These findings are leading to novel approaches to postexposure prophylaxis and therapy [10, 14, 20, 35].


Hemorrhagic Fever Cynomolgus Macaque Marburg Virus Hemorrhagic Fever Virus Primary Human Macrophage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andersson I, Lundkvist A, Haller O, Mirazimi A (2006) Type I interferon inhibits Crimean-Congo hemorrhagic fever virus in human target cells. J Med Virol 78:216–222.PubMedCrossRefGoogle Scholar
  2. 2.
    Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P, Fisher-Hoch SP, McCormick JB, Georges AJ (1999) Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5:423–426.PubMedCrossRefGoogle Scholar
  3. 3.
    Baize S, Leroy EM, Mavoungou E, Fisher-Hoch SP (2000) Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis 5:5–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, Negley D, Mohamadzadeh M, Bavari S, Schmaljohn A (2003) Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 188:1630–1638.PubMedCrossRefGoogle Scholar
  5. 5.
    Bray M (2005) Pathogenesis of viral hemorrhagic fever. Curr Opin Immunol 17:399–403.PubMedCrossRefGoogle Scholar
  6. 6.
    Bray M, Buller M (2004) Looking back at smallpox. Clin Infect Dis 38:882–889.PubMedCrossRefGoogle Scholar
  7. 7.
    Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J (1998) A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178:651–661.PubMedCrossRefGoogle Scholar
  8. 8.
    Bray M, Geisbert TW (2005) Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 37:1560–1566.PubMedCrossRefGoogle Scholar
  9. 9.
    Bray M, Mahanty S (2003) Ebola hemorrhagic fever and septic shock. J Infect Dis 188:1613–1617.PubMedCrossRefGoogle Scholar
  10. 10.
    Bray M, Paragas J (2002) Experimental therapy of filovirus infections. Antiviral Res 54:1–17.PubMedCrossRefGoogle Scholar
  11. 11.
    Burt FJ, Swanepoel R, Shieh WJ, Smith JF, Leman PA, Greer PW, Coffield LM, Rollin PE, Ksiazek TG, Peters CJ, Zaki SR (1997). Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis. Arch Pathol Lab Med 121:839–846.PubMedGoogle Scholar
  12. 12.
    Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, Katwidi DR, Kibadi K, Kipasa MA, Kuvula KJ, Mapanda BB, Massamba M, Mupapa KD, Muyembe-Tamfum JJ, Ndaberey E, Peters CJ, Rollin PE, Van den Enden E (1999) Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 179 (Suppl 1):S1–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, Jaax NK, Jahrling PB (1999) Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 179 (Suppl 1):S203–217.PubMedCrossRefGoogle Scholar
  14. 14.
    Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, Fritz EA, Fernando L, Kagan E, Jahrling PB, Hensley LE, Jones SM, Feldmann H (2006) Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367:1399–1404.PubMedCrossRefGoogle Scholar
  15. 15.
    Ergonul O (2006) Crimean-Congo haemorrhagic fever. Lancet Infect Dis 203–214.Google Scholar
  16. 16.
    Ergonul O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H (2004) Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 39:284–287.PubMedCrossRefGoogle Scholar
  17. 17.
    Ergonul O, Tuncbilek S, Baykam N, Celikbas A, Dokuzoguz B (2006) Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. J Infect Dis 193:941–944.PubMedCrossRefGoogle Scholar
  18. 18.
    Geisbert TW, Hensley LE (2004) Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 6:1–24.PubMedCrossRefGoogle Scholar
  19. 19.
    Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB (2000) Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 80:171–186.PubMedCrossRefGoogle Scholar
  20. 20.
    Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP (2003) Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362:1953–1958.PubMedCrossRefGoogle Scholar
  21. 21.
    Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, Scott DP, Kagan E, Jahrling PB, Davis KJ (2003) Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163:2347–2370.PubMedGoogle Scholar
  22. 22.
    Geisbert TW, Jahrling PB (2004) Exotic emerging viral diseases: progress and challenges. Nat Med 10:S110–121.PubMedCrossRefGoogle Scholar
  23. 23.
    Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE (2003) Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 188:1618–1629.PubMedCrossRefGoogle Scholar
  24. 24.
    Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, Hensley LE (2003) Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163:2371–2382.PubMedGoogle Scholar
  25. 25.
    Haller O, Kochs G, Weber F (2006) The interferon response circuit: induction and suppression by pathogenic viruses. Virology 344:119–130.PubMedCrossRefGoogle Scholar
  26. 26.
    Harcourt BH, Sanchez A, Offermann MK (1999) Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol 73:3491–3496.PubMedGoogle Scholar
  27. 27.
    Hensley LE, Young HA, Jahrling PB, Geisbert TW (2002) Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 80:169–179.PubMedCrossRefGoogle Scholar
  28. 28.
    Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348:138–150.PubMedCrossRefGoogle Scholar
  29. 29.
    Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE (2005) Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 174:5110–5118.PubMedGoogle Scholar
  30. 30.
    Hotchkiss RS, Tinsley KW, Karl IE (2003) Role of apoptotic cell death in sepsis. Scand J Infect Dis 35:585–592.PubMedCrossRefGoogle Scholar
  31. 31.
    Joubert JR, King JB, Rossouw DJ, Cooper R (1985) A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part III. Clinical pathology and pathogenesis. S Afr Med J 68:722–728.Google Scholar
  32. 32.
    Korth MJ, Kash JC, Furlong JC, Katze MG (2005) Virus infection and the interferon response: a global view through functional genomics. Methods Mol Med 116:37–55.PubMedGoogle Scholar
  33. 33.
    Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML, Swanepoel R, Burt FJ, Leman PA, Khan AS, Rowe AK, Mukunu R, Sanchez A, Peters CJ (1999) Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179 (Suppl 1):S177–187.Google Scholar
  34. 34.
    Mahanty S, Bray M (2004) Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4:487–498.PubMedCrossRefGoogle Scholar
  35. 35.
    Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B (2003) Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 170:2797–2801.PubMedGoogle Scholar
  36. 36.
    Paragas J, Geisbert TW (2006) Development of treatment strategies to combat Ebola and Marburg viruses. Expert Rev Anti Infect Ther 4:67–76.PubMedCrossRefGoogle Scholar
  37. 37.
    Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW (2004) Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol 17:390–400.PubMedCrossRefGoogle Scholar
  38. 38.
    Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD, Rollin PE (2004) Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 78:10370–10377.PubMedCrossRefGoogle Scholar
  39. 39.
    Smego RA, Jr., Sarwari AR, Siddiqui AR (2004) Crimean-Congo hemorrhagic fever: prevention and control limitations in a resource-poor country. Clin Infect Dis 38:1731–1735.PubMedCrossRefGoogle Scholar
  40. 40.
    van Eeden PJ, Joubert JR, van de Wal BW, King JB, de Kock A, Groenewald JH (1985) A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part I. Clinical features. S Afr Med J 68:711–717.Google Scholar
  41. 41.
    Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB, Zaki SR, Swanepoel R, Ansari AA, Peters CJ (1999) Markedly elevated levels of interferon (IFN)–gamma, IFN-alpha, interleukin (IL)–2, IL–10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 179 (Suppl 1):S188–191.PubMedCrossRefGoogle Scholar
  42. 42.
    Whitehouse CA (2004) Crimean-Congo hemorrhagic fever. Antiviral Res 64:145–160.PubMedGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • Mike Bray
    • 1
  1. 1.Division of Clinical ResearchNIAID, National Institutes of HealthBethesdaUSA

Personalised recommendations